<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389805</url>
  </required_header>
  <id_info>
    <org_study_id>UCDCC#158</org_study_id>
    <secondary_id>H3E-US-X038</secondary_id>
    <nct_id>NCT00389805</nct_id>
  </id_info>
  <brief_title>Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors</brief_title>
  <official_title>Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking
      some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed
      disodium may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of two different
      schedules of bortezomib when given together with pemetrexed disodium and to see how well they
      work in treating patients with advanced non-small cell lung cancer or other solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the safety, including dose-limiting toxicities, and feasibility of combining
           bortezomib with pemetrexed disodium in patients with advanced non-small cell lung cancer
           (NSCLC) or other solid tumors. (Phase I)

        -  Determine the response rate in patients with advanced NSCLC treated with this regimen.
           (Phase II)

      Secondary

        -  Compare the toxicity of 2 different schedules of bortezomib and pemetrexed disodium in
           patients with advanced solid tumors. (Phase I)

        -  Determine the maximum tolerated dose (MTD) of bortezomib when administered with
           pemetrexed disodium in 2 different treatment schedules in these patients. (Phase I)

        -  Determine, preliminarily, the efficacy of the combination of bortezomib and pemetrexed
           disodium in patients with advanced solid tumors. (Phase I)

        -  Assess the overall survival and progression-free survival of these patients. (Phase II)

        -  Evaluate the frequency and severity of toxicities associated with this regimen. (Phase
           II)

      Tertiary

        -  Perform laboratory correlative studies on tumor tissue and blood samples to investigate
           potential predictors of response. (Phase II)

      OUTLINE: This is a phase I, dose-escalation study of bortezomib followed by a phase II,
      open-label study.

        -  Phase I: Patients will be accrued, in an alternating fashion, to 1 of 2 treatment
           groups.

             -  Group I: Patients receive pemetrexed disodium IV on day 1 and bortezomib IV on days
                1, 4, 8, and 11.

             -  Group II: Patients receive pemetrexed disodium IV on day 1 and bortezomib IV on
                days 1 and 8.

      In both groups, treatment repeats every 21 days in the absence of unacceptable toxicity or
      disease progression.

      Cohorts of 3-6 patients per group receive escalating doses of bortezomib until the maximum
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2
      of 3 or 2 of 6 patients experience dose-limiting toxicity.

        -  Phase II: Patients receive pemetrexed disodium bortezomib (at the MTD) as in either
           group I or group II of the phase I portion of the study. Selection of the treatment
           schedule is based upon observed toxicity, safety, tolerability, efficacy, and clinical
           practicality.

      Blood is drawn at baseline and prior to courses 2 and 3 for correlative and molecular
      studies.

      Tumor tissue and blood samples from patients enrolled in the phase II portion of the study
      are examined for various biological markers. Immunohistochemistry is used to measure BCL-2
      gene, BCL-xL gene, BAX gene, and p27. Reverse transcriptase-polymerase chain reaction is used
      to assay the expression of thymidylate synthase, folsyl-polyglutamate synthase, and reduced
      folate carrier. Levels of plasminogen-activator inhibitor 1 gene, vascular endothelial growth
      factor, and osteopontin are measured by immunoenzyme techniques. The nuclear expression of
      NF-kB and p27 in blood is compared before and after study treatment by flow cytometry.

      After completion of study treatment, patients in phase I are followed for 30 days and
      patients in phase II are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Experiencing a Dose-limiting Toxicity (Phase I)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion or lasting &gt;7 days; febrile neutropenia; grade 3 neutropenia associated with infection; any other grade &gt;/=3 non-hematologic toxicity considered by the investigator to be related to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience Adverse Events (Phase I)</measure>
    <time_frame>Throughout the entire study (up to 36 months).</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v3.0 (Phase I).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Grade â‰¥ 3 Toxicity (Phase I)</measure>
    <time_frame>First cycle of treatment (3 weeks)</time_frame>
    <description>Grade 3/4 toxicity occurring in a patient within 1 cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Responded to Study Treatment (Phase II)</measure>
    <time_frame>From start of treatment until disease progression/recurrence.</time_frame>
    <description>To determine the response rate of bortezomib in combination with pemetrexed in patients with advanced NSCLC. Response rate was assessed by CT scan. CT scans was performed at baseline and every two cycles (prior to 3rd and 5th cycle). The evaluation of response was based on standard RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Toxicity by NCI CTC v3.0 (Phase I)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Adverse events possibly related to treatment, graded according to the NCI CTCAE v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose of Bortezomib in Combination With Pemetrexel (Phase I)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Efficacy as Measured by RECIST (Phase I)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Response to therapy was evaluated every 2 cycles according to RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicities (Phase II)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Each adverse event will be determined by using the NCI CTCAE, Version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Molecular Determinants in Tumor Samples (Phase II)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Expression of relevant molecular targets of the proteasome, which is inhibited by bortezomib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Importance of Folate-associated Gene Expression and Response or Outcome (Phase II)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Overexpression of reduced folate carrier (RFC) protein is thought to contribute to decreased resistance to pemetrexed. Levels of expression will be studied by measuring mRNA transcripts using quantitative Reverse Transcriptase-Polymerase Chain Reaction in archival patient tumor specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Bortezomib on Over Expression of NF-kB, BCL-2, and BCL-xL (Phase II)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Tumor levels of BCL-2, BCL-xL and BAX will be assessed by immunohistochemistry (IHC).</description>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Cytologically or histologically confirmed diagnosis of 1 of the following:

               -  Advanced solid tumor that progressed after standard therapy or for which no
                  effective curative therapy exists (phase I)

               -  Stage IIIB (pleural effusion) or IV non-small cell lung cancer (NSCLC) (phase II)

                    -  Disease must have progressed or recurred after 1 platinum-based therapy
                       regimen

                    -  NSCLC that has progressed or recurred after first-line therapy for stage
                       IIIA or IIIB disease allowed

          -  Measurable disease

               -  Disease in previously irradiated sites is considered measurable if there is clear
                  disease progression following radiotherapy

               -  Evaluable disease (bone metastases, pleural fluid, ascites) allowed (phase I)

          -  No symptomatic brain metastasis or disease requiring steroids and anticonvulsants

               -  Asymptomatic, previously treated (surgical resection or radiotherapy) brain
                  metastases allowed provided patient is neurologically stable and has been off
                  steroids and anticonvulsants for â‰¥ 4 weeks

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-2 (phase I) or 0-1 (phase II)

          -  Life expectancy â‰¥ 3 months

          -  Creatinine â‰¤ 1.5 mg/dL OR creatinine clearance â‰¥ 50 mL/min

          -  Bilirubin normal

          -  AST â‰¤ 2.5 times upper limit of normal

          -  Granulocyte count â‰¥ 1,500/mmÂ³

          -  Platelet count of â‰¥ 100,000/mmÂ³

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No pre-existing neuropathy â‰¥ grade 2

          -  No other prior malignancy except for the following (phase II):

               -  Adequately treated basal cell or squamous cell skin cancer

               -  In situ cervical cancer

               -  Adequately treated stage I or II cancer currently in complete remission

               -  Any other cancer from which the patient has been disease free for &gt; 5 years

          -  No hypersensitivity to bortezomib, boron, or mannitol

          -  No cardiovascular complications, including any of the following:

               -  Myocardial infarction within the past 6 months

               -  New York Heart Association class III-IV heart failure

               -  Uncontrolled angina

               -  Severe uncontrolled ventricular arrhythmias

               -  Electrocardiographic (ECG) evidence of acute ischemia or active conduction system
                  abnormalities

                    -  Any ECG abnormality at screening must be documented as not medically
                       relevant

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior bortezomib or pemetrexed disodium

          -  Any number of prior chemotherapy regimens allowed (phase I)

          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C) and recovered

          -  More than 2 weeks since prior radiotherapy and recovered

          -  No nonsteroidal anti-inflammatory drugs (NSAIDs) or salicylates 2 days prior and 2
             days after (5 days pre and post for long-acting NSAIDs) administration of pemetrexed
             disodium

          -  No concurrent anticonvulsants that are metabolized by the cytochrome P450 pathway
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Davies, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1112-6.</citation>
    <PMID>18090584</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <results_first_submitted>January 20, 2017</results_first_submitted>
  <results_first_submitted_qc>April 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2017</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Pemetrexed on day 1 (500 -600 mg/m2 IV) and bortezomib twice weekly (0.7-1.3mg/m3) on days 1, 4, 8, and 11 every 21 days</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Pemetrexed on day 1 (500 -600 mg/m2 IV) and bortezomib twice weekly (0.7-1.3mg/m2) on days 1 and 8 every 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">The Phase II study was not conducted.</participants>
                <participants group_id="P2" count="0">The Phase II study was not conducted.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="30" upper_limit="79"/>
                    <measurement group_id="B2" value="59" lower_limit="45" upper_limit="80"/>
                    <measurement group_id="B3" value="60" lower_limit="39" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Experiencing a Dose-limiting Toxicity (Phase I)</title>
        <description>Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion or lasting &gt;7 days; febrile neutropenia; grade 3 neutropenia associated with infection; any other grade &gt;/=3 non-hematologic toxicity considered by the investigator to be related to study drug.</description>
        <time_frame>Up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing a Dose-limiting Toxicity (Phase I)</title>
          <description>Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion or lasting &gt;7 days; febrile neutropenia; grade 3 neutropenia associated with infection; any other grade &gt;/=3 non-hematologic toxicity considered by the investigator to be related to study drug.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience Adverse Events (Phase I)</title>
        <description>Number of participants with treatment-related adverse events as assessed by CTCAE v3.0 (Phase I).</description>
        <time_frame>Throughout the entire study (up to 36 months).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Adverse Events (Phase I)</title>
          <description>Number of participants with treatment-related adverse events as assessed by CTCAE v3.0 (Phase I).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Grade â‰¥ 3 Toxicity (Phase I)</title>
        <description>Grade 3/4 toxicity occurring in a patient within 1 cycle.</description>
        <time_frame>First cycle of treatment (3 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade â‰¥ 3 Toxicity (Phase I)</title>
          <description>Grade 3/4 toxicity occurring in a patient within 1 cycle.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased transaminases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Responded to Study Treatment (Phase II)</title>
        <description>To determine the response rate of bortezomib in combination with pemetrexed in patients with advanced NSCLC. Response rate was assessed by CT scan. CT scans was performed at baseline and every two cycles (prior to 3rd and 5th cycle). The evaluation of response was based on standard RECIST criteria.</description>
        <time_frame>From start of treatment until disease progression/recurrence.</time_frame>
        <population>The Phase II study was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Responded to Study Treatment (Phase II)</title>
          <description>To determine the response rate of bortezomib in combination with pemetrexed in patients with advanced NSCLC. Response rate was assessed by CT scan. CT scans was performed at baseline and every two cycles (prior to 3rd and 5th cycle). The evaluation of response was based on standard RECIST criteria.</description>
          <population>The Phase II study was not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Toxicity by NCI CTC v3.0 (Phase I)</title>
        <description>Adverse events possibly related to treatment, graded according to the NCI CTCAE v3.0.</description>
        <time_frame>Up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Toxicity by NCI CTC v3.0 (Phase I)</title>
          <description>Adverse events possibly related to treatment, graded according to the NCI CTCAE v3.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased transaminases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea +/- vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Tolerated Dose of Bortezomib in Combination With Pemetrexel (Phase I)</title>
        <time_frame>Up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of Bortezomib in Combination With Pemetrexel (Phase I)</title>
          <units>Mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Efficacy as Measured by RECIST (Phase I)</title>
        <description>Response to therapy was evaluated every 2 cycles according to RECIST criteria.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>All patients for whom response evaluation measurements were recorded at baseline and after 2 cycles.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Efficacy as Measured by RECIST (Phase I)</title>
          <description>Response to therapy was evaluated every 2 cycles according to RECIST criteria.</description>
          <population>All patients for whom response evaluation measurements were recorded at baseline and after 2 cycles.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicities (Phase II)</title>
        <description>Each adverse event will be determined by using the NCI CTCAE, Version 3.0.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>The Phase II study was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicities (Phase II)</title>
          <description>Each adverse event will be determined by using the NCI CTCAE, Version 3.0.</description>
          <population>The Phase II study was not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Molecular Determinants in Tumor Samples (Phase II)</title>
        <description>Expression of relevant molecular targets of the proteasome, which is inhibited by bortezomib.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>The Phase II study was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Molecular Determinants in Tumor Samples (Phase II)</title>
          <description>Expression of relevant molecular targets of the proteasome, which is inhibited by bortezomib.</description>
          <population>The Phase II study was not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Importance of Folate-associated Gene Expression and Response or Outcome (Phase II)</title>
        <description>Overexpression of reduced folate carrier (RFC) protein is thought to contribute to decreased resistance to pemetrexed. Levels of expression will be studied by measuring mRNA transcripts using quantitative Reverse Transcriptase-Polymerase Chain Reaction in archival patient tumor specimens.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>The Phase II study was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Importance of Folate-associated Gene Expression and Response or Outcome (Phase II)</title>
          <description>Overexpression of reduced folate carrier (RFC) protein is thought to contribute to decreased resistance to pemetrexed. Levels of expression will be studied by measuring mRNA transcripts using quantitative Reverse Transcriptase-Polymerase Chain Reaction in archival patient tumor specimens.</description>
          <population>The Phase II study was not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Bortezomib on Over Expression of NF-kB, BCL-2, and BCL-xL (Phase II)</title>
        <description>Tumor levels of BCL-2, BCL-xL and BAX will be assessed by immunohistochemistry (IHC).</description>
        <time_frame>Up to 36 months</time_frame>
        <population>The Phase II study was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Bortezomib on Over Expression of NF-kB, BCL-2, and BCL-xL (Phase II)</title>
          <description>Tumor levels of BCL-2, BCL-xL and BAX will be assessed by immunohistochemistry (IHC).</description>
          <population>The Phase II study was not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea +/- vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased transaminases</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Analyst</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916-734-8053</phone>
      <email>nlogihara@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

